Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
The Management Board of Heidelberg Pharma today formally adopted a resolution, with the approval of the Supervisory Board, to conduct a rights issue in the amount of up to EUR 80 million. The securities prospectus has been approved by the German Federal Financial Supervisory Authority (BaFin). Heidelberg Pharma will implement the capital measure based on the prospectus and using Authorized Capital 2020/I as of 16 August 2022.